A Robust Control solution for Glycaemia Regulation of Type-1 Diabetes Mellitus

Cassany, Louis; Gucik‐Derigny, David; Cieslak, Jérôme; Henry, David; Franco, Roberto; Loza, Alejandra Ferreira de; Ríos, Héctor; Olçomendy, Loïc; Pirog, Antoine; Bornat, Yannick; Renaud, Sylvie; Catargi, Bogdan

doi:10.23919/ecc54610.2021.9654888

Cited by 3 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To design a controller K s (s) able to stabilize a family of systems of the nominal shaped plant Gs0 (s) = W 2 (s) G0 (s )W 1 (s), weighting functions W 1 (s) and W 2 (s) have to be defined. In a preliminary study (28), PID controllers achieved acceptable performance and the worst-case performance was observed for the patient 8 of the adult cohort. Thus, we selected W 2 = 1 and chose the continuous state-space representation of the individualised Proportional-Integral-Derivative (PID) controller dedicated to the eighth T1D patient for W 1 (s).…”

Section: Design Of the Unique Controller Kmentioning

confidence: 97%

“…Figure 6A shows the spatial discretization for the considered scenario. This protocol was thus repeated several times (a total of n = 222 models per patient) in order to have a family of linear models able to guarantee a good approximation of the nonlinear model equation (6), see (28) for more details.…”

Section: Getting a Family Of Linear Models Of T1d Patient Populationmentioning

confidence: 99%

“…This set of LTI models is composed of a nominal LTI model fitted with an uncertainty block and it can be used for design and analysis purpose. Based on this modelling, a unique and robust Proportional-Integral-Derivative (PID) has been designed for the T1DMS adult cohort in (28). Results reported in (28) showed that BG regulation fitted with a basic bolus strategy of 2 units of insulin applied during the meal announcement, provided quite similar performances with respect to the individualised PID controllers of (29).…”

Section: Introductionmentioning

confidence: 99%

“…Based on this modelling, a unique and robust Proportional-Integral-Derivative (PID) has been designed for the T1DMS adult cohort in (28). Results reported in (28) showed that BG regulation fitted with a basic bolus strategy of 2 units of insulin applied during the meal announcement, provided quite similar performances with respect to the individualised PID controllers of (29). These results motivated the use of a unique and robust controller to generate a continuous basal insulin injection.…”

Section: Introductionmentioning

confidence: 99%

“…In particular, we propose a method to define meal scenarios based on patients' body weight to better account for the interpatient variability in energy requirements and define more realistic meal scenarios. These scenarios are then used to assess the two different closed-loop solutions we already mentioned: the first one uses a GAbased controller tuning method (13,19) and the other one based on a robust control theory approach (28,31). With this second approach, we also propose a meal size-independent bolus strategy, slightly individualised by integrating the Carbohydrate-to-Insulin Ratio (CIR) in the bolus calculator rule.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

et al. 2022

Self Cite

View full text Add to dashboard Cite

In diabetes mellitus (DM) treatment, Continuous Glucose Monitoring (CGM) linked with insulin delivery becomes the main strategy to improve therapeutic outcomes and quality of patients’ lives. However, Blood Glucose (BG) regulation with CGM is still hampered by limitations of algorithms and glucose sensors. Regarding sensor technology, current electrochemical glucose sensors do not capture the full spectrum of other physiological signals, i.e., lipids, amino acids or hormones, relaying the general body status. Regarding algorithms, variability between and within patients remains the main challenge for optimal BG regulation in closed-loop therapies. This work highlights the simulation benefits to test new sensing and control paradigms which address the previous shortcomings for Type 1 Diabetes (T1D) closed-loop therapies. The UVA/Padova T1DM Simulator is the core element here, which is a computer model of the human metabolic system based on glucose-insulin dynamics in T1D patients. That simulator is approved by the US Food and Drug Administration (FDA) as an alternative for pre-clinical testing of new devices and closed-loop algorithms. To overcome the limitation of standard glucose sensors, the concept of an islet-based biosensor, which could integrate multiple physiological signals through electrical activity measurement, is assessed here in a closed-loop insulin therapy. This investigation has been addressed by an interdisciplinary consortium, from endocrinology to biology, electrophysiology, bio-electronics and control theory. In parallel to the development of an islet-based closed-loop, it also investigates the benefits of robust control theory against the natural variability within a patient population. Using 4 meal scenarios, numerous simulation campaigns were conducted. The analysis of their results then introduces a discussion on the potential benefits of an Artificial Pancreas (AP) system associating the islet-based biosensor with robust algorithms.

show abstract

Section: Design Of the Unique Controller Kmentioning

confidence: 97%

Section: Getting a Family Of Linear Models Of T1d Patient Populationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Further results on "non individualized" closed–loop for T1DM patients

Henry,

Cieslak,

Gucik-Derigny

et al. 2023

2023 IEEE Conference on Control Technology and Applications (CCTA)

View full text Add to dashboard Cite

Robust μ-Controller for Automatic Glucose Regulation for Type I Diabetes Mellitus

Kralev,

Slavov

2023

Mathematics

View full text Add to dashboard Cite

Type I diabetes mellitus is a serious autoimmune condition impacting a large population around the world that need a daily infusion of insulin substitutes to regulate blood glucose levels within healthy limits. The purpose of the study was to design a robust μ-controller based on an uncertain linear-time invariant (LTI) representation of the Hovorka model for glucose–insulin metabolism. The model set was obtained using linearization around an equilibrium point and adding parametric uncertainty to account for the time delay variation between plasma glucose concentration and its subcutaneous measurement. As a result, the robust stability and performance of the closed loop were proved using the structured singular value μ. The performance of the designed controller was also checked with a numerical simulation in connection with the nonlinear model.

show abstract

A Robust Control solution for Glycaemia Regulation of Type-1 Diabetes Mellitus

Cited by 3 publications

References 17 publications

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

Further results on "non individualized" closed–loop for T1DM patients

Robust μ-Controller for Automatic Glucose Regulation for Type I Diabetes Mellitus

Contact Info

Product

Resources

About